Dana-Farber Cancer Institute

NCT07499999

Phase 2Not yet recruiting140 people30 Mar 2026clinicaltrials.gov

NCT07426484

Phase 4Recruiting80 people23 Feb 2026clinicaltrials.gov

NCT07227584

Phase 2Recruiting67 people12 Nov 2025clinicaltrials.gov

NCT06664151

Early phase 1Recruiting25 people29 Oct 2024clinicaltrials.gov

NCT06001762

Phase 2Active, not recruiting90 people21 Aug 2023clinicaltrials.gov

NCT05655949

CollaboratorPhase 2Recruiting30 people19 Dec 2022clinicaltrials.gov

NCT05123131

CollaboratorPhase 2Active, not recruiting54 people17 Nov 2021clinicaltrials.gov

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

CollaboratorNo phaseActive, not recruiting353 people24 Sept 2021clinicaltrials.gov

NCT05050305

Phase 2Withdrawn0 people20 Sept 2021clinicaltrials.gov

NCT05016947

Phase 1Active, not recruiting23 people23 Aug 2021clinicaltrials.gov

NCT04850846

Phase 2Active, not recruiting60 people20 Apr 2021clinicaltrials.gov

NCT04732065

CollaboratorPhase 1Recruiting208 people1 Feb 2021clinicaltrials.gov

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Phase 2Active, not recruiting393 people30 Sept 2020clinicaltrials.gov

NCT04339062

Phase 1/2Completed12 people8 Apr 2020clinicaltrials.gov

NCT04150965

CollaboratorPhase 1/2Terminated14 people5 Nov 2019clinicaltrials.gov

NCT03740334

Phase 1Active, not recruiting45 people14 Nov 2018clinicaltrials.gov

NCT03716739

Phase 2Completed136 people23 Oct 2018clinicaltrials.gov

NCT03675893

Phase 2Recruiting110 people18 Sept 2018clinicaltrials.gov

NCT03227432

Phase 2Withdrawn0 people24 Jul 2017clinicaltrials.gov

NCT03087019

Phase 2Completed21 people22 Mar 2017clinicaltrials.gov